Drug intelligence / Profile preview

CBN-1100

Development stage: Preclinical
Lead developer: Carbon Biosciences
Modality: Viral Vectors → Gene Addition/Replacement → Gene Therapies
Administration: Systemic (likely Intravenous; Specific Route Not Detailed In Available Data)

Overview

CBN-1100 is an investigational gene therapy vector developed by Carbon Biosciences. It is designed to deliver genetic material systemically, with a demonstrated transgene packaging capacity of up to 5.9 kilobases—over 1 kilobase more than conventional adeno-associated virus (AAV) vectors[3][4]. Preclinical studies in nonhuman primates have shown that CBN-1100 is well-tolerated at high doses, with no significant cytokine response observed at the highest tested dose[1]. The vector’s enhanced packaging capacity may enable delivery of larger or multiple therapeutic genes compared to standard AAV-based therapies.

Beyond the preview

Go deeper on CBN-1100.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CBN-1100.

Explore the full profile